NASDAQ:WHWK Whitehawk Therapeutics (WHWK) Stock Price, News & Analysis $4.22 +0.15 (+3.69%) Closing price 04:00 PM EasternExtended Trading$4.17 -0.05 (-1.16%) As of 05:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Whitehawk Therapeutics Stock (NASDAQ:WHWK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Whitehawk Therapeutics alerts:Sign Up Key Stats Today's Range$3.97▼$4.2450-Day Range$3.16▼$5.1052-Week Range$1.57▼$5.49Volume167,725 shsAverage Volume425,768 shsMarket Capitalization$208.68 millionP/E RatioN/ADividend YieldN/APrice Target$7.33Consensus RatingModerate Buy Company Overview Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California. Read More Whitehawk Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreWHWK MarketRank™: Whitehawk Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 29th out of 79 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingWhitehawk Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialWhitehawk Therapeutics has a consensus price target of $7.33, representing about 73.8% upside from its current price of $4.22.Amount of Analyst CoverageWhitehawk Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Whitehawk Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Whitehawk Therapeutics are expected to decrease in the coming year, from ($1.44) to ($1.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Whitehawk Therapeutics is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Whitehawk Therapeutics is -2.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWhitehawk Therapeutics has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.33% of the float of Whitehawk Therapeutics has been sold short.Short Interest Ratio / Days to CoverWhitehawk Therapeutics has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Whitehawk Therapeutics has recently increased by 5.72%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWhitehawk Therapeutics does not currently pay a dividend.Dividend GrowthWhitehawk Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.11 News SentimentWhitehawk Therapeutics has a news sentiment score of 0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Whitehawk Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for WHWK on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows1 people have added Whitehawk Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Whitehawk Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,584,564.00 in company stock.Percentage Held by Insiders49.90% of the stock of Whitehawk Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.08% of the stock of Whitehawk Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Whitehawk Therapeutics' insider trading history. Receive WHWK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Whitehawk Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WHWK Stock News HeadlinesWhitehawk Therapeutics to Participate in the TD Cowen 7th Annual Oncology Innovation SummitMay 20 at 8:00 AM | prnewswire.comWhitehawk Therapeutics officer Ball sells $201k in stockMay 18 at 1:48 AM | investing.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 20 at 1:00 AM | Behind the Markets (Ad)Whitehawk Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology ForumMay 15, 2026 | prnewswire.comWhitehawk’s First-in-Human PTK7 ADC Trial Moves Ahead: What Investors Should KnowMay 14, 2026 | theglobeandmail.comWhitehawk Therapeutics secures $87.5M PIPE financingMay 14, 2026 | seekingalpha.comWhitehawk Therapeutics Announces $87.5M Private Placement Equity FinancingMay 13, 2026 | prnewswire.comWhitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent HighlightsMay 7, 2026 | finanznachrichten.deSee More Headlines WHWK Stock Analysis - Frequently Asked Questions How have WHWK shares performed this year? Whitehawk Therapeutics' stock was trading at $2.42 at the start of the year. Since then, WHWK stock has increased by 74.4% and is now trading at $4.22. How were Whitehawk Therapeutics' earnings last quarter? Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) issued its quarterly earnings results on Thursday, May, 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.36) by $0.04. Who are Whitehawk Therapeutics' major shareholders? Top institutional shareholders of Whitehawk Therapeutics include Stempoint Capital LP (1.90%), Renaissance Technologies LLC (0.87%), Eversept Partners LP (0.62%) and ADAR1 Capital Management LLC (0.26%). Insiders that own company stock include David James Lennon, Bryan Ball and Scott M Giacobello. View institutional ownership trends. How do I buy shares of Whitehawk Therapeutics? Shares of WHWK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today5/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (7m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 WHWK's financial health is in the Green zone, according to TradeSmith. WHWK has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Pharmaceutical Preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:WHWK CIK1422142 WebN/A Phone(424) 473-8055FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Price Target for Whitehawk Therapeutics$7.33 High Price Target$8.00 Low Price Target$7.00 Potential Upside/Downside+73.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.60 million Net MarginsN/A Pretax Margin-288.26% Return on Equity-79.63% Return on Assets-74.01% Debt Debt-to-Equity RatioN/A Current Ratio11.36 Quick Ratio11.36 Sales & Book Value Annual Sales$7.14 million Price / Sales29.23 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book1.80Miscellaneous Outstanding Shares49,450,000Free Float24,775,000Market Cap$208.68 million OptionableN/A Beta0.70 Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:WHWK) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredAre we ignoring the same signal Wall Street ignored in 1929?In 1929, Irving Weiss spotted a systemic crisis hiding beneath record highs and shorted the market - turning $...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSaudi Arabia just broke its 50-year dollar arrangementSaudi Arabia has quietly walked away from its 1974 petrodollar agreement with the U.S. - the pact that require...Golden Portfolio | SponsoredFed story no one is tellingJ.P. Morgan's Private Bank quietly advised 333 billionaire families to move 60% of their portfolios into alter...TradeSmith | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Whitehawk Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Whitehawk Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
